Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Industry Focus

Industry Focus

Edit Profile
Episodes
1101
Followers
Listens
70082
×  

Follow This Show

Stay in the know about new episodes and updates.
Featured Host
Healthcare, technology, energy, consumer goods, and more. If you're looking for deeper insights on today’s top industries then this podcast is for you.

On-Demand Episodes

On the surface, White Mountains Insurance’s business model may look a lot like the Oracle of Omaha’s playbook.
Play Now

This week, a judge approved the AT&T/Time Warner $85B deal. Why does the telecom giant want a piece of the content world, and what does the deal mean for the marketplace? Thanks to Blooom for supporting Industry Focus. Get a... more
Play Now

Eugene Mulero, Capitol Hill reporter for Transport Topics, recently visited Project Neon, a $1 billion interstate project in Nevada. He discusses the projects progress and how the Nevada state government secured both federal and... more
Play Now

Celgene's been stumbling lately, but it's got irons in the fire that could get it back on track. Are this company's best days behind it, or are they only beginning? Stocks: CELG
Play Now

Celgene's been stumbling lately, but it's got irons in the fire that could get it back on track. Are this company's best days behind it, or are they only beginning? Stocks: CELG
Play Now

As the “retail apocalypse” bears down on brick-and-mortar chains across the country, some department stores are showing signs of strength. Shareholders are cheering the impressive year-to-date rallies, but will the party last? Stocks: M,... more
Play Now

Here’s what investors need to know about three big news items. Get a month free with blooom401k.com/fool and code fool .
Play Now

We've got Fool.com's Brian Feroldi back on to talk under-the-radar tech stocks. He walks us through why Grubhub, Mitek, and BlackLine are currently on his watchlist. Stocks: (NYSE: GRUB) (NASDAQ: MITK) (NASDAQ: BL)
Play Now

After facing continuing construction delays caused by political challenges and permitting concerns, Kinder Morgan sold its Trans Mountain Pipeline and expansion project to the Canadian government. We discuss what that means for... more
Play Now

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD
Play Now

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled